Pharmaceutical Executive
February 01, 2012
Issue PDF
0
0
Brand of the Year : Abbott's Humira
February 01, 2012
Column
0
0
For a rendering to be effective, the right balance must be struck between captivating art and accurate science.
February 01, 2012
Column
0
0
State tech transfer laws giving universities automatic ownership of employees' inventions represent a threat to pharma partnerships-but the Supreme Court is poised to intervene in the industry's favor.
February 01, 2012
Features
0
0
Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".
February 01, 2012
From the Editor
0
0
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
February 01, 2012
Country Report
0
0
Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.
February 01, 2012
0
0
Brazilian industry is learning to spread its pharma manufacturing around more.
February 01, 2012
Column
0
0
After two years of waiting, FDA issued the first in a series of planned guidelines on social media at the end of last year. We look at some of the experts' reactions.
February 01, 2012
Column
0
0
Sarah Krug asks if it is time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
February 01, 2012
0
0
Astellas makes its presence felt in Brazil.
February 01, 2012
0
0
French-based Besins is a relatively new entrant to the Brazilian pharma market.
February 01, 2012
Column
0
0
Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?
February 01, 2012
Column
0
0
The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
February 01, 2012
0
0
Torrent's affiliate in Brazil has become the India-based company's biggest.
February 01, 2012
Column
0
0
Time to stop and think about CMS's 'Proposed Rule' on transparency and what it means for the life sciences business model.
February 01, 2012
0
0
Biominas helps foster the development of biotech-related businesses in Brazil.